In late December 2018, the results of a large head-to-head superiority trial in adults with psoriatic arthritis (PsA) were announced.1 This study was a Phase 3b/4, open-label, randomized, parallel-group, controlled clinical trial, comparing on-label doses of ixekizumab and adalimumab along with use of concomitant conventional disease-modifying antirheumatic drugs (DMARDs).
Explore this issueFebruary 2019
Also by this Author
Blinded outcome assessments were used to evaluate the efficacy and safety of ixekizumab compared with adalimumab in PsA patients who were biologic DMARD-naive over a 52-week treatment period. The primary efficacy endpoints were simultaneous achievement of ACR50 and PASI100 response at Week 24. Major secondary endpoints included demonstration of non-inferiority in ACR50 and superiority in PASI100 in ixekizumab-treated patients compared with adalimumab-treated patients.
Patients (N=566) could be enrolled in the study if they had active PsA and plaque psoriasis (body surface area involvement of at least 3%) and had an inadequate response to at least one conventional DMARD.
Patients with active PsA were randomized to receive a 160 mg starting dose of ixekizumab followed by 80 mg of ixekizumab every four weeks, or 40 mg of adalimumab every two weeks, for a total of 52 weeks. The primary analysis was conducted at Week 24.